Kristjan Gunnarsson

ArcanaBio is modeling a digital twin of your health, from proteins. A molecular portrait that updates every day from a drop of saliva, powered by our patented technology. A continuous conversation with your own biology for a long and healthy life. Healthcare is reactive. You feel symptoms, you get tested, you get treated. Scientific wellness promises a different future, one that is predictive, preventive, and personalized. But today that future still requires blood draws, clinical infrastructure, and expensive panels. It remains inaccessible to the vast majority of people. ArcanaBio removes those barriers. Our patented platform detects protein biomarkers directly from saliva, without reagents, labels, or lab processing. Combined with AI-powered analysis, we transform raw biological signals into continuous, actionable health insights. Based at the BioInnovation Institute in Copenhagen, with operations in Iceland, Denmark, and Austria, ArcanaBio is backed by the Novo Nordisk Foundation and supported by EU grant partnerships across Europe. We hold a granted US patent and are advancing toward our first commercial offering in 2026. Our roadmap moves from lab services to a home device to a wearable, progressively putting molecular health monitoring into the hands of every person, every day.